Recent immunohistochemical data indicate that this tumor type is generally negative for classical hormone receptors such as estrogen receptor (ER) and progesterone receptor (PR), while frequently expressing androgen receptors (AR), corresponding to an ER−/PR−/AR+ profile. The gene discussed is PGR; the disease is neoplasm.